HAVANA, Cuba, Feb 6 (ACN) The Cuban medication known as Heberprot-P to treat diabetic food ulcers began to be administered in Seychelles islands, in what is known as an experimental stage, according to reports from the capital Victoria.
In order to compare the results of the medication, 20 patients were included in a study with half of them being administered the Cuban pharmaceutical, while the other half will continue to receive traditional treatment.
Heberprot-B is exclusively produced by Cuba's Genetic Engineering and Biotechnology Center from recombinant human growth factor and it has proven its superiority over other medications currently being prescribed to treat diabetic foot ulcers.
According to the Cuban embassy in Seychelles the experimental study is being conducted by Cuban angiologist Neobalis Franco, who is offering her services as a medical collaborator in the Indian Ocean archipelago under the advice of doctor Manuel Raices, from the Cuban Genetic Engineering and Biotechnology Center.
The scientific project also counts on the participation of Doctor Henry Telemaque, who heads surgery services at Victoria's Hospital and a medical advisor to Seychelles' government.
According to the World Health Organization, diabetes is currently affecting over 300 million people in the world, while diabetic foot ulcers constitute one of the worst complications, needing the largest costs in resources for health systems in different countries.